Human albumin is a type of protein, commonly found in human blood plasma. Human albumin is normally synthesized in liver. Factor Vlll is a blood clotting protein and also known as anti-hemophilic factor (AHF). Defect in production of Factor Vlll may result in hemophilia A (genetic deficiency in clotting factor). This protein circulates in bloodstream in an inactive form. In response to the injury, factor Vlll initiates the chemical reaction that forms a blood clot. Factor Vlll are also extracted from the human plasma or engineered from mammalian cell culture by means of recombinant DNA technology and can be used to treat patients with hemophilia disease.
Rising incidences of hemophilia will drive the growth of the market of human albumin and factor VIII market. According to National Hemophilia Foundation, approximately one in 5,000 male in the U.S. are affected with hemophilia. In addition, strategic collaboration by key players in order to introduce novel treatment options will further drive the market growth. For example, Novo Nordisk collaborated with National Hemophilia Foundation aiming to develop novel treatment option for hemophilia disease. Thus, these types of collaboration will build healthy platform to attract new customers and hence drive the market growth. Furthermore, rising geriatric population will significantly drive the market growth of human albumin and factor VIII market. According to a report published by World Health Organization (WHO), the number of people aged 65 years and above is expected to increase from 605 million to 2 billion by 2050. Additionally, advances in factor VIII product resulted in a major increase in quality of life of patients and hence supports the growth of human albumin and factor VIII. Moreover, various other factors like rising number of people with bleeding disorders, rising use of albumin as cell culture medium ingredient and low cost therapy will further augment the growth of the market. However, stringent regulation and lack of adequate plasma supplies will restrain the growth of human albumin and factor VIII market. In addition, high cost of therapies coupled with lack of adequate treatment modalities in developing countries like Asia-Pacific will restrain the growth of this market. For example, advanced therapeutics for the treatment are only available in the developed countries like North America and Europe.
Geographically, North America dominates the global human albumin and factor VIII market. Increasing use of plasma derived products in North America will drive the growth of human albumin and factor VIII market in North America. Europe is considered as the second largest market of human albumin and factor VIII market. The growth of the market in Europe is majorly driven by aging population. Rise in geriatric population will increase the risk of the people diagnosed with hemophilia which drives the growth of human albumin and factor VIII market in European market. According to Eurostat (European Commission) report published in 2013, around 17.8% of the European population were aged 65 years and above. The market of human albumin and factor VIII market in Asia-Pacific holds a strong growth as there is a rise in total number of bleeding disorder cases in this region. In addition, emerging countries like India and China are increasingly importing albumins from western countries (i.e. North America and Europe) which will ultimately drive the overall growth of this market in Asia-Pacific region.
Some of the key players dominating the global human albumin and factor VIII market comprises Baxter International, Inc., Talecris Plasma Resources, Grifols, S.A., Novo Nordisk, CSL Limited and others.
This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.
The scrutiny of the various forces impacting the dynamics of the market, and key and associated industries, guides enterprises in understanding various consumer propositions. Our clients leverage these insights and perspectives to enhance customer experience in the fast-paced business environment.
All our insights and perspectives are broadly based on 4 Pillars or Stages: ASBC-S, which offer an elaborate and customizable framework for the success of an organization. The essence and the roles of these in organizational successes are highlighted below:
- Agenda for CXOs: TMR, through the study, sets the tone for agendas that are pertinent to CEOs, CFOs, CIOs, and other CXO executives of businesses operating in the market. The perspectives help our clients to bridge the gap between agenda and action plan. TMR strives to offer guidance to CXOs to undertake mission-critical activities empowered by various business analysis tools, and boost the performance of the organizations. The perspectives guide you to decide on your own marketing mix that align well with the policies, visions, and mission.
- Strategic Frameworks: The study offers how organizations are setting both short-term and long-term strategic plans. Our team of experts collaborate and communicate with you to understand these to make your organizations sustainable and resilient during tough times. The insights help them decide sustainable competitive advantage for each business units.
- Benchmarking for Deciding Target Markets and Brand Positioning: The assessments in the study provides a scrutiny of marketing channels and marketing mix. Our various teams work synergistically with you to help identify your actual and potential direct, indirect, and budget competition areas. Additionally, the study helps you decide most effective budgets for various processes and promotional activities. Furthermore, the study guides you to set benchmarks for integrating people and processes with the 4Ps of marketing. Eventually, this will empower you to find out unique propositioning strategies and niches.
- Business Composability for Sustainability (C-S): Constant strategy planning for sustainability characterizing our C-S framework in the report has become more relevant than before in the face of disruptions caused by pandemics, recessions, boom and bust cycles, and changing geopolitical scenario. The TMR study offers a high level of customization to help you achieve business composability. Composable enterprises are increasingly gaining the attention of CXOs in order to help them combat market volatility. Our analysts and industry experts help you wade through such uncertainties and guide you to become a smart sustainable business in entirety.
The study presents scrutiny of region-specific consumer and technology trends, including the most recent industry dynamics. These broadly cover but not limited to
- North America, South America, and the Americas
- Asia Pacific and Japan
- Latin America
- Middle East and Africa
The study offers data-driven insights and guidance of several aspects. Some of the more notable questions are:
- What are the major recent trends that can influence the product life cycle and the RoI?
- Which regulatory trends shape corporate-level, business-level, and functional-level strategies?
- Which micromarketing initiatives of leading players will bring in investments?
- What can be the best framework and tools for PESTLE analysis?
- Which regions will witness rise in new opportunities?
- Which are the game-changing technologies being used to capture new revenue streams in the near future?
- Which operational and tactical frameworks are being adopted by various players in gaining customer loyalty?
- What is the current and expected intensity of competition the market in the near future?
Disclaimer: This market research study is an ongoing effort and extreme care has been taken to maintain the highest levels of accuracy at all stages. However, in the light of the rapidly evolving business dynamics, some region-specific or other segment-specific changes may take time to be part of the study.